Literature DB >> 30952628

A Case of ANCA-Associated Vasculitis.

Jonathan J Hogan1.   

Abstract

Entities:  

Keywords:  ANCA; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; glomerulonephritis; vasculitis

Year:  2019        PMID： 30952628      PMCID： PMC6500935          DOI： 10.2215/CJN.14601218

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  9 in total

1.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.

Authors:  Shivani Shah; Zdenka Hruskova; Marten Segelmark; Matthew D Morgan; Jonathan Hogan; Steven K Lee; Jessica Dale; Lorraine Harper; Vladimir Tesar; David R W Jayne; Duvuru Geetha
Journal:  Am J Nephrol       Date:  2015-06-02       Impact factor: 3.754

3.  Histopathological Classification and Renal Outcome in Patients with Antineutrophil Cytoplasmic Antibodies-associated Renal Vasculitis: A Study of 186 Patients and Metaanalysis.

Authors:  Yong-Xi Chen; Jing Xu; Xiao-Xia Pan; Ping-Yan Shen; Xiao Li; Hong Ren; Xiao-Nong Chen; Li-Yan Ni; Wen Zhang; Nan Chen
Journal:  J Rheumatol       Date:  2016-12-15       Impact factor: 4.666

4.  Efficacy of remission-induction regimens for ANCA-associated vasculitis.

Authors:  Ulrich Specks; Peter A Merkel; Philip Seo; Robert Spiera; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Barri J Fessler; Linna Ding; Lisa Viviano; Nadia K Tchao; Deborah J Phippard; Adam L Asare; Noha Lim; David Ikle; Brett Jepson; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Mark Mueller; Lourdes P Sejismundo; Kathleen Mieras; John H Stone
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

5.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

Authors:  Loïc Guillevin; Christian Pagnoux; Alexandre Karras; Chahera Khouatra; Olivier Aumaître; Pascal Cohen; François Maurier; Olivier Decaux; Jacques Ninet; Pierre Gobert; Thomas Quémeneur; Claire Blanchard-Delaunay; Pascal Godmer; Xavier Puéchal; Pierre-Louis Carron; Pierre-Yves Hatron; Nicolas Limal; Mohamed Hamidou; Maize Ducret; Eric Daugas; Thomas Papo; Bernard Bonnotte; Alfred Mahr; Philippe Ravaud; Luc Mouthon
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

6.  Rituximab for treatment of severe renal disease in ANCA associated vasculitis.

Authors:  Duvuru Geetha; Zdenka Hruskova; Marten Segelmark; Jonathan Hogan; Matthew D Morgan; Teresa Cavero; Per Eriksson; Philip Seo; Rebecca L Manno; Jessica Dale; Lorraine Harper; Vladimir Tesar; David Rw Jayne
Journal:  J Nephrol       Date:  2015-05-19       Impact factor: 3.902

7.  Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear.

Authors:  Michael Walsh; Alina Casian; Oliver Flossmann; Kerstin Westman; Peter Höglund; Charles Pusey; David R W Jayne
Journal:  Kidney Int       Date:  2013-04-24       Impact factor: 10.612

8.  The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.

Authors:  Rennie L Rhee; John C Davis; Linna Ding; Fernando C Fervenza; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; W Joseph McCune; Paul A Monach; Philip Seo; Robert Spiera; E William St Clair; Ulrich Specks; John H Stone; Peter A Merkel
Journal:  Clin J Am Soc Nephrol       Date:  2018-01-25       Impact factor: 8.237

9.  Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).

Authors:  Pierre Charles; Benjamin Terrier; Élodie Perrodeau; Pascal Cohen; Stanislas Faguer; Antoine Huart; Mohamed Hamidou; Christian Agard; Bernard Bonnotte; Maxime Samson; Alexandre Karras; Noémie Jourde-Chiche; François Lifermann; Pierre Gobert; Catherine Hanrotel-Saliou; Pascal Godmer; Nicolas Martin-Silva; Grégory Pugnet; Marie Matignon; Olivier Aumaitre; Jean-François Viallard; François Maurier; Nadine Meaux-Ruault; Sophie Rivière; Jean Sibilia; Xavier Puéchal; Philippe Ravaud; Luc Mouthon; Loïc Guillevin
Journal:  Ann Rheum Dis       Date:  2018-04-25       Impact factor: 19.103
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.